stockrowResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
Follow RMD
Alert me
ResMed Inc. (RMD) Return on equity
ResMed Inc.'s return on equity over the twelve months to 30 September 2026 was 26.4%, up 2.1 percentage points from fiscal 2026 (24.3%). Over the past ten years it has ranged from 15.7% (fiscal 2018) to 27.2% (fiscal 2020); the current reading is higher than 75% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 24.3% | (1.59) |
| FY2025 | 25.9% | 3.16 |
| FY2024 | 22.7% | (1.26) |
| FY2023 | 24.0% | (1.00) |
| FY2022 | 25.0% | 7.33 |
| FY2021 | 17.6% | (9.58) |
| FY2020 | 27.2% | 7.62 |
| FY2019 | 19.6% | 3.89 |
| FY2018 | 15.7% | (3.03) |
| FY2017 | 18.7% | (2.74) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| RMD ResMed Inc. | 26.4% |
| WST West Pharmaceutical Services, Inc. compare | 21.2% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| BDX Becton, Dickinson and Company compare | 3.77% |
| SOLV Solventum Corporation compare | 3.19% |
| MDLN Medline Inc. compare | 3.18% |
| ALC Alcon compare | 2.94% |
| ALGN Align Technology, Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −10.6% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement